Many breast cancer cells facing potentially lethal antiestrogen therapy recycle to survive, researchers say.

Gefitinib, the once-promising drug formerly approved as a second line treatment for lung cancer, also known as Iressa, enhanced the effectiveness of hormonal therapy for the treatment of specific types of metastatic breast cancer, according to a Phase II clinical trial led by researchers at The University of Texas M. D. Anderson Cancer Center.

A combination of molecular-targeted therapy and hormonal therapy may be the most promising area of research for those seeking an effective treatment for ovarian cancer, according to a new review in the International Journal of Gynecological Cancer.